1. Home
  2. RDHL vs PRPO Comparison

RDHL vs PRPO Comparison

Compare RDHL & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDHL
  • PRPO
  • Stock Information
  • Founded
  • RDHL 2009
  • PRPO N/A
  • Country
  • RDHL Israel
  • PRPO United States
  • Employees
  • RDHL N/A
  • PRPO N/A
  • Industry
  • RDHL Biotechnology: Pharmaceutical Preparations
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • RDHL Health Care
  • PRPO Industrials
  • Exchange
  • RDHL Nasdaq
  • PRPO Nasdaq
  • Market Cap
  • RDHL 8.2M
  • PRPO 9.9M
  • IPO Year
  • RDHL N/A
  • PRPO N/A
  • Fundamental
  • Price
  • RDHL $5.23
  • PRPO $7.22
  • Analyst Decision
  • RDHL
  • PRPO
  • Analyst Count
  • RDHL 0
  • PRPO 0
  • Target Price
  • RDHL N/A
  • PRPO N/A
  • AVG Volume (30 Days)
  • RDHL 10.4K
  • PRPO 5.9K
  • Earning Date
  • RDHL 04-07-2025
  • PRPO 03-28-2025
  • Dividend Yield
  • RDHL N/A
  • PRPO N/A
  • EPS Growth
  • RDHL N/A
  • PRPO N/A
  • EPS
  • RDHL N/A
  • PRPO N/A
  • Revenue
  • RDHL $3,707,000.00
  • PRPO $17,411,000.00
  • Revenue This Year
  • RDHL $224.90
  • PRPO $75.18
  • Revenue Next Year
  • RDHL $82.69
  • PRPO N/A
  • P/E Ratio
  • RDHL N/A
  • PRPO N/A
  • Revenue Growth
  • RDHL N/A
  • PRPO 31.31
  • 52 Week Low
  • RDHL $5.20
  • PRPO $4.31
  • 52 Week High
  • RDHL $20.28
  • PRPO $7.55
  • Technical
  • Relative Strength Index (RSI)
  • RDHL 31.92
  • PRPO 62.56
  • Support Level
  • RDHL $5.52
  • PRPO $7.02
  • Resistance Level
  • RDHL $5.71
  • PRPO $7.55
  • Average True Range (ATR)
  • RDHL 0.27
  • PRPO 0.25
  • MACD
  • RDHL -0.04
  • PRPO 0.05
  • Stochastic Oscillator
  • RDHL 2.38
  • PRPO 73.78

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Share on Social Networks: